微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 15.13% | -0.04% | 56.51% | 138/159 | 31.52% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 9.67% | -9.05% | -2.51% | 147/159 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 9.91% | -11.86% | -4.64% | 148/159 | 22.98% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 10.4% | 7.27% | -31.3% | 148/159 | 33.39% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 15.13% | 44.36% | 42.41% | 142/159 | 51.73% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 10.63% | -41.08% | -5.53% | 147/159 | 51.53% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 11.25% | -40.53% | 16.07% | 145/159 | 32.76% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 9.69% | -52.01% | -7.56% | 145/159 | 38.65% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 10.48% | -57.25% | -41.88% | 142/159 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 18.04% | -40.86% | -4.65% | 145/159 | 53.74% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 18.91% | -40.68% | -6.34% | 136/159 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 20.19% | -42.68% | -17.64% | 141/159 | 21.74% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 24.52% | -32.21% | -19.6% | 128/159 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 30.5% | -24.58% | -4.35% | 126/159 | 55.21% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 31.89% | -27.27% | -9.5% | 107/159 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 35.23% | -20.31% | -2.59% | 113/159 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 36.17% | -13.57% | -10.56% | 95/159 | 54.21% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 40.44% | -6.2% | -7.76% | 106/159 | -144.37% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 43.84% | 3.24% | -0.84% | 84/159 | 56.57% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 44.21% | 10.9% | 5.65% | 89/159 | 54.32% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 41.85% | 18.28% | -2.93% | 81/159 | 55.5% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 43.11% | 15.72% | 1.51% | 91/159 | -1213.38% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 42.47% | 8.73% | 6.52% | 73/159 | 55.47% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 39.87% | 0.45% | 12.68% | 82/159 | 55.47% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 35.38% | -9.56% | -5.03% | 86/159 | 51.37% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 37.25% | -2.47% | -4.62% | 101/159 | -205.91% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 39.06% | 0.83% | -1.59% | 75/159 | 54.25% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 39.69% | -0.15% | 1.45% | 74/159 | 53.68% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 39.12% | -3.82% | 2.42% | 75/159 | 54.19% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 38.2% | -10.65% | -1.38% | 81/159 | 52.58% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 38.73% | -9.67% | -2.55% | 64/159 | 49.32% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 39.75% | -5.14% | -2.28% | 65/159 | 48.02% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 40.67% | -7.26% | -4.86% | 48/159 | 46.89% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 42.75% | 20.51% | -0.31% | 63/159 | 48.44% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 42.88% | 29.27% | 2.34% | 41/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 41.9% | 29.03% | -4.46% | 47/159 | 46.2% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 43.86% | 44.7% | 23.63% | 37/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 35.47% | 29.92% | 6.94% | 69/159 | 46.24% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 33.17% | 2% | 2.15% | 53/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 32.47% | 2% | 7.15% | 57/159 | 45.36% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 30.31% | 2% | 11% | 50/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |